New trial
Phase 1/2 trial of CGT4859, an FGFR2/3 inhibitor, in advanced solid tumors
- Trial ID
- NCT06777316 on ClinicalTrials.gov
- Cancer type
- Other Solid Tumors
- Stage of research
- First-in-human
- Location
- 10 Locations
- Published in
- New in Oncology - July 3, 2025
This open-label study evaluates the safety, dosing, and antitumor activity of oral CGT4859 administered via dose escalation and expansion in adults with unresectable or metastatic intrahepatic cholangiocarcinoma and advanced solid tumors harboring FGFR2/3 alterations. Sponsor Cogent Biosciences conducts the trial across multiple US sites.
More in multiple solid tumors
-
Trial result · Oct 15, 2026 · NCT04985604
Tovorafenib (type II RAF inhibitor; BRAF/CRAF) drives 43% ORR in BRAF/RAF1-altered R/R solid tumors -
New trial · Oct 15, 2026 · NCT07819136
Phase 1/2 ZINNIA tests REC-7735, a PIK3CA H1047R-selective inhibitor, across advanced solid tumors -
New trial · Oct 15, 2026 · NCT07843550
Phase 1/2 larotrectinib plus pembrolizumab tests TRK inhibition after checkpoint failure in lung adenocarcinoma and melanoma -
New trial · Oct 15, 2026 · NCT07832630
Phase 2 saruparib tests PARP1 inhibition in HRD-signature-positive solid tumors without prior platinum resistance -
New trial · Oct 15, 2026 · NCT07811297
Phase 1b/2a catequentinib tests angiogenesis blockade alone and in combinations across four solid-tumor settings